Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the. On June 23, TD Cowen analyst Tyler Van Buren began coverage of the com ...

Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” ...

Soleno Therapeutics (NASDAQ:SLNO) traded higher on Tuesday after Betaville said in a report that the Redwood City, California ...

FDA approval of VYKAT XR for hyperphagia in Prader-Willi Syndrome marks a major milestone for Soleno Therapeutics.

REDWOOD CITY, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment ...

Conference is the first-ever international meeting jointly hosted by the Prader-Willi Syndrome Association | USA, the ...

Soleno Therapeutics, Inc. announced its participation in the 2025 United In Hope: International Prader-Willi Syndrome Conference, scheduled for June 24-28, 2025, in Phoenix, AZ.

Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome Provided by GlobeNewswire Mar 26, 2025, 9:15:58 PM.

Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) saw unusually-high trading volume on Monday after HC Wainwright raised their price target on the stock from $70.00 to $100.00.

Soleno Therapeutics (NASDAQ:SLNO – Get Free Report) had its price target upped by stock analysts at Laidlaw from $75.00 to $105.00 in a research note issued to investors on Thursday, ...